Italia markets closed

PFE Mar 2025 40.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
11,300,00 (0,00%)
Alla chiusura: 11:55AM EDT
Schermo intero
Chiusura precedente11,30
Aperto11,50
Denaro10,95
Domanda11,50
Prezzo d'esercizio40,00
Scadenza2025-03-21
Min-Max giorno11,30 - 11,50
Contratto - Min-MaxN/D
Volume11
Open Interest405
  • GlobeNewswire

    Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

    NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal g